1、C-suite barometer:sector viewLife sciences&pharmaceuticalsContents4 Foreword6 Executive summary7 Investing in research and development11 Addressing the power of emerging technologies14 Exploring the international landscape20 Expectations from current affairsC-suite barometer:life sciences&pharmaceut

2、icalsForvis Mazars4ForewordAt the end of 2024,we collected the views of leaders worldwide for our annual C-suite barometer.Over 1,700 executives from more than 35 countries contributed,revealing a determination to continue growing amid a more competitive and challenging environment.The results of ou

3、r C-suite barometer offer an opportunity to gain first-hand insights into the life sciences&pharmaceuticals sector.It identifies the opportunities and challenges leaders in the sector face and what they see as key strategic priorities over the next five years.Sharing such knowledge allows sector pla

4、yers to benchmark their concerns and strategic focus against their peers.At the same time,the results allow us to understand and support our clients in addressing their challenges and helping them achieve their objectives more effectively.What is striking about this years findings is the high levels

5、 of optimism in the life sciences&pharmaceuticals sector,with 98%of C-suite leaders indicating a positive growth outlook for their businesses in 2025.What is behind such optimism are robust drug pipelines and significant investments in research and development(R&D),allowing the sector to grow revenu

6、es that put it in a strong position to support future growth ambitions.Divesting non-core activities has also allowed companies to prioritise drug development and quickly bring new products to market.In addition,venture capitalists are investing in the sector,which is helping to fund R&D and clinica